Caribou Biosciences Stock Alpha and Beta Analysis
| CRBU Stock | USD 2.02 0.04 2.02% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Caribou Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Caribou Biosciences over a specified time horizon. Remember, high Caribou Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Caribou Biosciences' market risk premium analysis include:
Beta 3.17 | Alpha (0.33) | Risk 4.81 | Sharpe Ratio 0.0021 | Expected Return 0.0103 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Caribou |
Caribou Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Caribou Biosciences market risk premium is the additional return an investor will receive from holding Caribou Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Caribou Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Caribou Biosciences' performance over market.| α | -0.33 | β | 3.17 |
Caribou Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Caribou Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Caribou Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Caribou Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Caribou Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Caribou Biosciences shares will generate the highest return on investment. By understating and applying Caribou Biosciences stock market price indicators, traders can identify Caribou Biosciences position entry and exit signals to maximize returns.
Caribou Biosciences Return and Market Media
The median price of Caribou Biosciences for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 1.98 with a coefficient of variation of 11.56. The daily time series for the period is distributed with a sample standard deviation of 0.24, arithmetic mean of 2.04, and mean deviation of 0.16. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Analyst reaffirms Buy on Caribou Biosciences stock after FDA Fast Track designations - Investing.com | 09/04/2024 |
2 | Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 | 09/25/2024 |
3 | Acquisition by Khan Ruhi Ahmad of 131000 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 | 10/01/2024 |
4 | Acquisition by Rachel Haurwitz of 10000 shares of Caribou Biosciences at 2.96 subject to Rule 16b-3 | 10/03/2024 |
5 | Insider Trading | 10/04/2024 |
6 | STATE STREET CORPs Strategic Acquisition in Caribou Biosciences Inc | 10/17/2024 |
7 | Vanguard Group Incs Strategic Acquisition in Caribou Biosciences Inc | 11/05/2024 |
8 | Caribou Biosciences Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag | 11/08/2024 |
9 | Steven Cohens Strategic Acquisition in Caribou Biosciences Inc | 11/15/2024 |
10 | Critical Analysis Caribou Biosciences versus AIM ImmunoTech | 11/18/2024 |
11 | Acquisition by Rizvi Syed Ali-aamir of 131000 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 | 11/22/2024 |
About Caribou Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Caribou or other stocks. Alpha measures the amount that position in Caribou Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 15.15 | 9.25 | 11.97 | 7.04 | Net Debt To EBITDA | 3.64 | 0.29 | 0.21 | 0.2 |
Caribou Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Caribou Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Caribou Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Caribou Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Caribou Biosciences. Please utilize our Beneish M Score to check the likelihood of Caribou Biosciences' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Caribou Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.